Veloxis Pharmaceuticals Announces Financial Results For The First Half 2013 Daily Markets (press release) Veloxis has completed two Phase III studies of LCP-Tacro™ in kidney transplant recipients as the basis for its development programme for LCP-Tacro™ as a once-daily agent for the prophylaxis of organ rejection in kidney transplantation. The first of ... |
